Please login to the form below

Not currently logged in
Email:
Password:

Cancer Drug Fund

This page shows the latest Cancer Drug Fund news and features for those working in and with pharma, biotech and healthcare.

NICE turns down Opdivo for adjuvant melanoma therapy

NICE turns down Opdivo for adjuvant melanoma therapy

NICE turns down Opdivo for adjuvant melanoma therapy. BMS drug currently only licensed treatment in this setting. ... It also says it cannot recommend the drug for use within the Cancer Drugs Fund (CDF) “because… it is not possible to assess whether

Latest news

  • Keytruda achieves cost effectiveness milestone, first to exit Cancer Drugs Fund Keytruda achieves cost effectiveness milestone, first to exit Cancer Drugs Fund

    This means it will now be removed from the ‘managed access’Cancer Drugs Fund (CDF) the first drug to achieve this since the remodelled system was launched two years ago. ... It’s nearest competitor in front line NSCLC treatment is Tecentriq,

  • NICE U-turn on Opdivo for kidney cancer NICE U-turn on Opdivo for kidney cancer

    guidance. Opdivo (nivolumab) is now set to be recommended as a second-line treatment on the NHS in England and Wales almost immediately as the Cancer Drugs Fund will support the ... happy that NICE has made this recommendation for patients with advanced

  • Reformed Cancer Drugs Fund backs its first drug - AZ’s Tagrisso Reformed Cancer Drugs Fund backs its first drug - AZ’s Tagrisso

    Reformed Cancer Drugs Fund backs its first drug - AZ’ s Tagrisso. ... AstraZeneca's Tagrisso (osimertinib) has become the first drug to be supported by the UK's newly-reformed Cancer Drugs Fund (CDF).

  • Pfizer warns against price-cutting after NICE backs Bosulif Pfizer warns against price-cutting after NICE backs Bosulif

    Pfizer warns against price-cutting after NICE backs Bosulif. Cancer drug is the first to be re-appraised form the CDF. ... NICE has approved the first re-appraised drug from the now-defunct Cancer Drugs Fund (CDF) - but Pfizer has warned that companies

  • Imbruvica wins wider European leukaemia licence Imbruvica wins wider European leukaemia licence

    AbbVie and Johnson &Johnson have been granted a European licence for the expanded use of their chemotherapy alternative drug Imbruvica. ... Despite Imbruvica's status as the most requested CLL drug available on the Cancer Drugs Fund (CDF), the

More from news
Approximately 1 fully matching, plus 28 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics